Dr. Fangli Chen is a partner in the Litigation Department and chair of the Life Sciences Patent Practice. She represents all types of companies in the biotech and pharmaceutical industries, and has deep scientific expertise and a strong business sense. Fangli effectively identifies and transforms technological developments into valuable intellectual property assets for her clients and specializes in the strategic development of complex IP portfolios for companies that align with their business goals.
Fangli’s practice also focuses on post-grant review before the USPTO, oppositions, pre-litigation and litigation strategy, due diligence investigations, freedom-to-operate, non-infringement and invalidity analysis, licensing and other IP matters in connection with commercial transactions. She handles a variety of technology areas including biochemistry, molecular and cell biology, immunotherapy, enzyme replacement therapy, nucleic acid based technologies including messenger RNA therapy, gene therapy, gene editing, antisense and oligonucleotides based therapies, vaccines, bioinformatics, and small molecule compound drugs.
Fangli also has a wealth of experience in the following areas:
- Post-grant challenges: representing clients in inter partes review interference and various foreign opposition proceedings.
- Technology transactions & licensing: advising clients on matters relating to technology or material transfer, licensing and research collaborations.
- Investment or acquisition counsel: assisting investors in assessing the technology and intellectual property assets and risks for potential target investments and counseling companies on intellectual property matters in connection with public offering or acquisition.
Fangli has been repeatedly noted for her top-tier work by industry publications, including being listed as a World’s Leading Patent Practitioner by IAM Patent 1000 and recognized as one of the Top 250 Women in IP nationwide by Managing Intellectual Property. In 2019, she was named Patent Strategy & Management Attorney of the Year in Massachusetts by LMG Life Sciences. She has also been recognized by Best Lawyers in America, Client Choice, Legal 500, Massachusetts Lawyers Weekly and Massachusetts Super Lawyers. Prior to joining Proskauer, Fangli was a partner at a leading Boston law firm.
Education
-
Suffolk University Law School, J.D.
cum laude
-
Massachusetts Institute of Technology, Ph.D.
-
Fudan University, B.S.
highest distinction
Admissions & Qualifications
- Massachusetts
- U.S. Patent and Trademark Office
Court Admissions
- U.S. District Court, Massachusetts
- U.S. Court of Appeals, Federal Circuit
Awards & Recognition
Best Lawyers in America 2016-2025
IAM Patent Global Leader 2022-2025
IAM Patent 1000: The World’s Leading Patent Practitioners 2016-2021, 2023
Client Choice 2015
Chambers USA: Massachusetts: Intellectual Property 2023-24
LMG Life Sciences: Life Sciences Star 2017-2021
LMG Life Sciences: Patent Strategy Attorney of the Year - Massachusetts 2019
Massachusetts Lawyers Weekly, "Top Women of Law" 2017-2018
Massachusetts Lawyers Weekly, “Up & Coming Lawyer”
Massachusetts Super Lawyers, “Super Lawyer” 2017-2018
Managing Intellectual Property US Patent Prosecution Practitioner of the Year 2021
Managing Intellectual Property, “Top 250 Women in IP” 2021-2023
Managing Intellectual Property IP STARS 2020-2021, 2023
The Legal 500 United States: Healthcare: Life Sciences 2019-2024
The Legal 500 United States: General Commercial Disputes 2020
Matters
Representative Matters
- Representation of a biotech company in defending its key patent in inter partes review.
- Strategic representation of large biopharmaceutical company with regard to their product protection, life cycle management, clearance study and IP diligence in connection with acquisition, license and other business partnership.
- Strategic representation of biotech start-up company with regard to protection of their key product, freedom-to-operate and management of their relationship with large biotech partners.
- IP counsel to pharmaceutical companies and universities for managing portfolios in areas of pharmacogenomics, recombinant technologies, molecular biology, bioinformatics, drug discovery and small molecules.
Patent Law